Converge Biotech and Mylin Biotech Collaborate to Launch Enzewhey 98 for Critically ill Patients
Converge Biotech, a leading healthcare company in the critical care segment, and Mylin Biotech, an innovative company in the nutrition space, have collaborated to market “Enzewhey 98”, a breakthrough product featuring the research-based innovation Enzotein*, in India.
“Enzewhey 98” is a product designed for critically ill patients requiring RT and JT feeding.
“Enzewhey 98” is an unique product which is used as meal replacement therapy addressing the Cephalic Phase of digestion.
Converge Biotech is a leading healthcare company with diversified business verticals, while Mylin Biotech is a research-based organization specializing in the manufacturing of Symbiotics, Enzobiotics, and Enzotein, with a global presence.
